A comprehensive atlas of pediatric immune checkpoint inhibitors-related adverse events: From real-world pharmacovigilance data to mechanistic insights

Abstract

Background: Immune checkpoint inhibitors (ICIs) are widely used in childhood cancer, posing challenges with associated ICIs-related adverse events (irAEs). This study focuses on pediatric irAEs and explores underlying mechanisms.

Methods: Data on ICI-related adverse reactions were gathered from two sources: VigiBase database (1967–2023) and the FDA Adverse Event Reporting System (FAERS) database (2013–2022). Disproportionality analysis (Reporting odds ratio, proportional reporting ratio, information component) compared pediatric and adult cancer patients using ICIs. Integration with the Gene Expression Omnibus (GEO) database explored potential biological mechanisms.

Results: We identified four categories of pediatric irAEs in the VigiBase and FAERS databases, including cytokine release syndrome (ROR_VigiBase = 17.05; ROR_FAERS = 14.17), acute respiratory distress syndrome (ROR_VigiBase = 10.26; ROR_FAERS = 12.39), seizure (ROR_VigiBase = 7.18; ROR_FAERS = 10.63), and febrile neutropenia (FN) (ROR_VigiBase = 3.01; ROR_FAERS = 4.84). The development of irAEs in pediatric patients potentially involves various pathways: immune activation, inflammatory imbalance, pathogen recognition systems, decreased inhibitory synapses, altered E/I ratios, and CNS abnormalities.

Conclusions: This study explores pediatric irAEs, revealing potential mechanisms and stressing tailored prevention for young cancer patients on ICIs, providing theoretical insights for better management.

Keywords

Children / FAERS / Immune checkpoint inhibitors / Immunotherapy / VigiBase

References

[1] Paz-Ares L, Spira A, Raben D, et al. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial. Ann Oncol. 2020; 31(6): 798-806.

[2] Migden MR, Rischin D, Schmults CD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018; 379(4): 341-351.

[3] Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021; 16: 223-249.

[4] Yu L, Huang K, Liao Y, Wang L, Sethi G, Ma Z. Targeting novel regulated cell death: ferroptosis, pyroptosis and necroptosis in anti-PD-1/PD-L1 cancer immunotherapy. Cell Prolif. 2024; 57(8):e13644.

[5] Zhang N, Zhang H, Liu Z, et al. An artificial intelligence network-guided signature for predicting outcome and immunotherapy response in lung adenocarcinoma patients based on 26 machine learning algorithms. Cell Prolif. 2023; 56(4):e13409.

[6] Liang H, Lu Q, Yang J, Yu G. Supramolecular biomaterials for cancer immunotherapy. Research (Wash DC). 2023; 6:0211.

[7] Liu J, Liu W, Wan Y, Mao W. Crosstalk between exercise and immunotherapy: current understanding and future directions. Research (Wash DC). 2024; 7:0360.

[8] Tan R, Zhao J, Shubhra QTH. Eclipsing toxicity, enhancing efficacy: Clofazimine's vanguard in the realm of anti-PD-1 and CTLA-4 immunotherapy. Research (Wash DC). 2024; 7:0419.

[9] Melaiu O, Lucarini V, Giovannoni R, Fruci D, Gemignani F. News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors. Semin Cancer Biol. 2022; 79: 18-43.

[10] Long AH, Morgenstern DA, Leruste A, Bourdeaut F, Davis KL. Checkpoint immunotherapy in pediatrics: here, gone, and back again. Am Soc Clin Oncol Educ Book. 2022; 42: 1-14.

[11] Bouffet E, Larouche V, Campbell BB, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol. 2016; 34(19): 2206-11.

[12] Geoerger B, Kang HJ, Yalon-Oren M, et al. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trial. Lancet Oncol. 2020; 21(1): 121-133.

[13] Widemann BC. Immune checkpoint inhibitors for refractory childhood cancers. Lancet Oncol. 2020; 21(1): 14-15.

[14] Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018; 378(2): 158-168.

[15] Nigro O, Ferrari A, Casanova M, et al. Controversies on the possible role of immune checkpoint inhibitors in pediatric cancers: balancing irAEs and efficacy. Tumori. 2021; 107(4): 276-281.

[16] Zhou C, Peng S, Lin A, et al. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine. 2023; 59:101967.

[17] Lin A, Zheng K, Jiang A, et al. The evolving landscape of immunotoxicity: charting mechanisms and future strategies for immune checkpoint inhibitor adverse events. Med Research. 2025;

[18] Merchant MS, Wright M, Baird K, et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res. 2016; 22(6): 1364-70.

[19] Geoerger B, Zwaan CM, Marshall LV, et al. Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1–2 study. Lancet Oncol. 2020; 21(1): 134-144.

[20] Davis KL, Fox E, Merchant MS, et al. Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1–2 trial. Lancet Oncol. 2020; 21(4): 541-550.

[21] Ihara K. Immune checkpoint inhibitor therapy for pediatric cancers: a mini review of endocrine adverse events. Clin Pediatr Endocrinol. 2019; 28(3): 59-68.

[22] Kabir TF, Chauhan A, Anthony L, Hildebrandt GC. Immune checkpoint inhibitors in pediatric solid tumors: status in 2018. Ochsner J. Winter2018; 18(4): 370-376.

[23] Dasgupta A, Tsay E, Federman N, Lechner MG, Su MA. Polyendocrine autoimmunity and diabetic ketoacidosis following anti-PD-1 and interferon α. Pediatrics. 2022; 149(4):e2021053363.

[24] Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020; 6(1): 38.

[25] Zhu X, McDowell MM, Newman WC, Mason GE, Greene S, Tamber MS. Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report. J Neurosurg Pediatr. 2017; 19(2): 249-253.

[26] Mandel JJ, Olar A, Aldape KD, Tremont-Lukats IW. Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci. 2014; 344(1-2): 229-31.

[27] Iglesias P, Soria A, Díez JJ. [Autoimmune endocrinopathies induced by immunomodulating antibodies in the treatment of cancer]. Med Clin (Barc). 2015; 145(6): 264-8. Endocrinopatías autoinmunitarias inducidas por anticuerpos inmunomoduladores en el tratamiento del cáncer.

[28] Ragoonanan D, Khazal SJ, Abdel-Azim H, et al. Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. Nat Rev Clin Oncol. 2021; 18(7): 435-453.

[29] Lindquist M. VigiBase, the WHO Global ICSR Database System: basic facts. Drug Inf J. 2008; 42(5): 409-419.

[30] Li H, Sun X, Sun D, et al. Thromboembolic events associated with immune checkpoint inhibitors: a real-world study of data from the Food and Drug Administration adverse event reporting system (FAERS) database. Int Immunopharmacol. 2021; 98:107818.

[31] Lansdown G, Vaghri Z. Article 1: Definition of a Child. In: Vaghri Z, Zermatten J, Lansdown G, Ruggiero R, eds. Monitoring state compliance with the UN convention on the rights of the child: an analysis of attributes. Springer International Publishing; 2022: 407-412.

[32] Gastaldon C, Arzenton E, Raschi E, et al. Neonatal withdrawal syndrome following in utero exposure to antidepressants: a disproportionality analysis of VigiBase, the WHO spontaneous reporting database. Psychol Med. 2023; 53(12): 5645-5653.

[33] Khaleel MA, Khan AH, Ghadzi SMS, Adnan AS, Abdallah QM. A standardized dataset of a spontaneous adverse event reporting system. Healthcare (Basel). 2022; 10(3): 420.

[34] Caster O, Aoki Y, Gattepaille LM, Grundmark B. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations. Drug Saf. 2020; 43(5): 479-487.

[35] Yu Y, Chen J, Li D, Wang L, Wang W, Liu H. Systematic analysis of adverse event reports for sex differences in adverse drug events. Sci Rep. 2016; 6:24955.

[36] Dolladille C, Ederhy S, Sassier M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020; 6(6): 865-871.

[37] Cirenajwis H, Ekedahl H, Lauss M, et al. Molecular stratification of metastatic melanoma using gene expression profiling: prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget. 2015; 6(14): 12297-309.

[38] Kabbarah O, Nogueira C, Feng B, et al. Integrative genome comparison of primary and metastatic melanomas. PLoS One. 2010; 5(5):e10770.

[39] Avery-Kiejda KA, Bowden NA, Croft AJ, et al. P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer. 2011; 11: 203.

[40] Riker AI, Enkemann SA, Fodstad O, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics. 2008; 1: 13.

[41] Xu L, Shen SS, Hoshida Y, et al. Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res. 2008; 6(5): 760-9.

[42] Kim SJ, Sohn I, Do IG, et al. Gene expression profiles for the prediction of progression-free survival in diffuse large B cell lymphoma: results of a DASL assay. Ann Hematol. 2014; 93(3): 437-47.

[43] Scott DW, Wright GW, Williams PM, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014; 123(8): 1214-7.

[44] Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet. 2012; 44(12): 1321-5.

[45] Shaknovich R, Geng H, Johnson NA, et al. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood. 2010; 116(20): e81-9.

[46] Kuo HP, Ezell SA, Schweighofer KJ, et al. Combination of Ibrutinib and ABT-199 in diffuse large B-cell lymphoma and follicular lymphoma. Mol Cancer Ther. 2017; 16(7): 1246-1256.

[47] Lee Y, Scheck AC, Cloughesy TF, et al. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics. 2008; 1: 52.

[48] Sun L, Hui AM, Su Q, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 2006; 9(4): 287-300.

[49] Walsh AM, Kapoor GS, Buonato JM, et al. Sprouty2 drives drug resistance and proliferation in glioblastoma. Mol Cancer Res. 2015; 13(8): 1227-37.

[50] Berendsen S, van Bodegraven E, Seute T, et al. Adverse prognosis of glioblastoma contacting the subventricular zone: biological correlates. PLoS One. 2019; 14(10):e0222717.

[51] Tso CL, Shintaku P, Chen J, et al. Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res. 2006; 4(9): 607-19.

[52] Gao Y, Weenink B, van den Bent MJ, et al. Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. Eur J Cancer. 2018; 94: 168-178.

[53] Khan AB, Lee S, Harmanci AS, et al. CXCR4 expression is associated with proneural-to-mesenchymal transition in glioblastoma. Int J Cancer. 2023; 152(4): 713-724.

[54] Gorovets D, Kannan K, Shen R, et al. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clin Cancer Res. 2012; 18(9): 2490-501.

[55] Best MG, In ’t Veld S, Sol N, Wurdinger T. RNA sequencing and swarm intelligence-enhanced classification algorithm development for blood-based disease diagnostics using spliced blood platelet RNA. Nat Protoc. 2019; 14(4): 1206-1234.

[56] Huang T, Yang Y, Song X, et al. PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. Mol Cell. 2021; 81(6): 1276-1291 e9.

[57] Hänzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14: 7.

[58] Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43): 15545-50.

[59] Zhang J, Li H, Tao W, Zhou J. GseaVis: an R package for enhanced visualization of gene set enrichment analysis in biomedicine. Med Research. 2025; 1(1): 131-135.

[60] Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009; 462(7269): 108-12.

[61] Jing Y, Liu J, Ye Y, et al. Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. Nat Commun. 2020; 11(1): 4946.

[62] Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160(1-2): 48-61.

[63] Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018; 48(4): 812-830.e14.

[64] Ginestet C. ggplot2: elegant graphics for data analysis. J Royal Stat Soc Series A Stat Soc. 2011; 174(1): 245-246.

[65] Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012; 16(5): 284-7.

[66] Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016; 32(18): 2847-9.

[67] Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome. J Immunother Cancer. 2018; 6(1): 56.

[68] Ceschi A, Noseda R, Palin K, Verhamme K. Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO Global Pharmacovigilance Database. Front Pharmacol. 2020; 11: 557.

[69] Sumi T, Koshino Y, Michimata H, et al. Cytokine release syndrome in a patient with non-small cell lung cancer on ipilimumab and nivolumab maintenance therapy after vaccination with the mRNA-1273 vaccine: a case report. Transl Lung Cancer Res. 2022; 11(9): 1973-1976.

[70] Tay SH, Toh MMX, Thian YL, et al. Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature. Front Immunol. 2022; 13:807050.

[71] Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2): 188-95.

[72] Meyer NJ, Gattinoni L, Calfee CS. Acute respiratory distress syndrome. Lancet. 2021; 398(10300): 622-637.

[73] Bos LDJ, Ware LB. Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes. Lancet. 2022; 400(10358): 1145-1156.

[74] Reuss JE, Suresh K, Naidoo J. Checkpoint inhibitor pneumonitis: mechanisms, characteristics, management strategies, and beyond. Curr Oncol Rep. 2020; 22(6): 56.

[75] Reuss JE, Anagnostou V, Cottrell TR, et al. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother Cancer. 2020; 8(2):e001282.

[76] Bellmunt J, Hussain M, Gschwend JE, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22(4): 525-537.

[77] Takebayashi Y, Neshige S, Hayashi T, et al. A case of repetitive seizures following immune checkpoint inhibitor therapy as a feature of autoimmune encephalitis. Epileptic Disord. 2021; 23(5): 733-738.

[78] Satake T, Maruki Y, Kubo Y, et al. Atezolizumab-induced encephalitis in a patient with hepatocellular carcinoma: a case report and literature review. Intern Med. 2022; 61(17): 2619-2623.

[79] Navrátil L, Pospísil J, Blehová Z. [Changes in the level of prostanoids in blood during whole-body irradiation of rats]. Sb Lek. 1988; 90(10): 302-9. Zmĕny koncentrace nĕkterých prostanoidů v plazmĕ u celotĕlovĕ ozárených potkanů.

[80] Nader R, Tannoury E, Rizk T, Ghanem H. Atezolizumab-induced encephalitis in a patient with metastatic breast cancer: a case report and review of neurological adverse events associated with checkpoint inhibitors. Autops Case Rep. 2021; 11:e2021261.

[81] Stuby J, Herren T, Schwegler Naumburger G, Papet C, Rudiger A. Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature. Swiss Med Wkly. 2020; 150:w20377.

[82] Patel K, West HJ. Febrile neutropenia. JAMA Oncol. 2017; 3(12): 1751.

[83] Seguchi K, Nakashima K, Terao T, Takeshita G, Nagai T, Tanaka Y. Febrile neutropenia in a patient with non-small-cell lung cancer treated with atezolizumab: a case report. Respir Med Case Rep. 2021; 33:101439.

[84] Michot JM, Lazarovici J, Tieu A, et al. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Eur J Cancer. 2019; 122: 72-90.

[85] Zhao W, Zhang Y, Zhang P, et al. High programmed death 1 expression on T cells in aplastic anemia. Immunol Lett. 2017; 183: 44-51.

[86] Tabchi S, Weng X, Blais N. Severe agranulocytosis in a patient with metastatic non-small-cell lung cancer treated with nivolumab. Lung Cancer. 2016; 99: 123-6.

[87] Wright Z, Brown A. High-grade neutropenia in a patient successfully treated with nivolumab for refractory primary mediastinal B-cell lymphoma. Blood Adv. 2017; 1(17): 1306-1308.

[88] Lu D. Children's immunity at risk. New Sci. 2021; 250(3332): 8-9.

[89] Carsetti R, Quintarelli C, Quinti I, et al. The immune system of children: the key to understanding SARS-CoV-2 susceptibility? Lancet Child Adolesc Health. 2020; 4(6): 414-416.

[90] Smith LS, Zimmerman JJ, Martin TR. Mechanisms of acute respiratory distress syndrome in children and adults: a review and suggestions for future research. Pediatr Crit Care Med. 2013; 14(6): 631-43.

[91] Nardou R, Ferrari DC, Ben-Ari Y. Mechanisms and effects of seizures in the immature brain. Semin Fetal Neonatal Med. 2013; 18(4): 175-84.

[92] Wahli MN, Hayoz S, Hoch D, et al. The role of immune checkpoint inhibitors in clinical practice: an analysis of the treatment patterns, survival and toxicity rates by sex. J Cancer Res Clin Oncol. 2023; 149(7): 3847-3858.

[93] Choi J, Lee SY. Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors. Immune Netw. 2020; 20(1):e9.

[94] Muenchhoff M, Goulder PJ. Sex differences in pediatric infectious diseases. J Infect Dis. 2014; 209 Suppl 3(Suppl 3): S120-6.

[95] Zhong L, Wu Q, Chen F, Liu J, Xie X. Immune-related adverse events: promising predictors for efficacy of immune checkpoint inhibitors. Cancer Immunol Immunother. 2021; 70(9): 2559-2576.

[96] Liu Y, Shepherd EG, Nelin LD. MAPK phosphatases–regulating the immune response. Nat Rev Immunol. 2007; 7(3): 202-12.

[97] Li G, Wan Y, Jiao A, et al. Breaking boundaries: chronic diseases and the frontiers of immune microenvironments. Med Research. 2025; 1(1): 62-102.

[98] Manohar SM. At the crossroads of TNF α signaling and cancer. Curr Mol Pharmacol. 2024; 17:e060923220758.

[99] Sha L, Wu X, Yao Y, et al. Notch signaling activation promotes seizure activity in temporal lobe epilepsy. Mol Neurobiol. 2014; 49(2): 633-44.

[100] Wang DD, Benkli B, Auguste KI, et al. Unilateral holohemispheric central nervous system lesions associated with medically refractory epilepsy in the pediatric population: a retrospective series of hemimegalencephaly and Rasmussen's encephalitis. J Neurosurg Pediatr. 2014; 14(6): 573-84.

[101] Treiman DM. GABAergic mechanisms in epilepsy. Epilepsia. 2001; 42 Suppl 3: 8-12.

[102] Zhao J, Sun J, Zheng Y, et al. Activated astrocytes attenuate neocortical seizures in rodent models through driving Na(+)-K(+)-ATPase. Nat Commun. 2022; 13(1): 7136.

[103] Dolladille C, Ederhy S, Allouche S, et al. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020; 8(1):e000261.

[104] Shen J, Hu R, Lin A, et al. Characterization of second primary malignancies post CAR T-cell therapy: real-world insights from the two global pharmacovigilance databases of FAERS and VigiBase. EClinicalMedicine. 2024; 73:102684.

[105] Park JA, Cheung NV. Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. Cancer Treat Rev. 2017; 58: 22-33.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.